These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 19025828)

  • 1. The New Zealand intensive medicines monitoring programme in pro-active safety surveillance.
    Coulter DM
    Pharmacoepidemiol Drug Saf; 2000 Jul; 9(4):273-80. PubMed ID: 19025828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
    Clark DW; Harrison-Woolrych M
    Curr Drug Saf; 2006 May; 1(2):169-78. PubMed ID: 18690928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The New Zealand Intensive Medicines Monitoring Programme.
    Coulter DM
    Pharmacoepidemiol Drug Saf; 1998 Mar; 7(2):79-90. PubMed ID: 15073731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approach.
    Coulter DM
    Drug Saf; 2002; 25(6):433-9. PubMed ID: 12071780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Privacy issues and the monitoring of sumatriptan in the New Zealand Intensive Medicines Monitoring Programme.
    Coulter DM
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):663-7. PubMed ID: 11980258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena).
    Zhou L; Harrison-Woolrych M; Coulter DM
    Pharmacoepidemiol Drug Saf; 2003; 12(5):371-7. PubMed ID: 12899110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data.
    Layton D; Heeley E; Shakir SA
    J Clin Pharm Ther; 2004 Apr; 29(2):171-81. PubMed ID: 15068407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-marketing surveillance in New Zealand.
    Edwards IR
    Med Toxicol; 1986; 1 Suppl 1():83-5. PubMed ID: 3821432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription-event monitoring: developments in signal detection.
    Ferreira G
    Drug Saf; 2007; 30(7):639-41. PubMed ID: 17604421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug metabolism genotypes and their association with adverse drug reactions in selected populations: a pilot study of methodology.
    Clark D; Morgan A; Hananeia L; Coulter D; Olds R
    Pharmacoepidemiol Drug Saf; 2000 Sep; 9(5):393-400. PubMed ID: 19025845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hair loss with use of the levonorgestrel intrauterine device.
    Paterson H; Clifton J; Miller D; Ashton J; Harrison-Woolrych M
    Contraception; 2007 Oct; 76(4):306-9. PubMed ID: 17900442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electronic capture of dispensing data by the New Zealand Intensive Medicines Monitoring Programme: a consultation study of community and hospital pharmacists.
    Harrison-Woolrych M; Jamieson S; Malik M; Holt A; Herbison P
    Int J Pharm Pract; 2011 Apr; 19(2):136-9. PubMed ID: 21385245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruising associated with sibutramine: results from postmarketing surveillance in New Zealand.
    Harrison-Woolrych M; Hill GR; Clark DW
    Int J Obes (Lond); 2006 Aug; 30(8):1315-7. PubMed ID: 16491106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
    Buggy Y; Layton D; Fogg C; Shakir SA
    Epilepsia; 2010 May; 51(5):818-29. PubMed ID: 20132298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme.
    Hill GR; Ashton J; Harrison-Woolrych M
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1217-26. PubMed ID: 17661435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance of a recently switched non-prescription medicine (Diclofenac) using a pharmacy-based approach.
    Gauld NJ; Shaw JP; Emmerton LM; Pethica BD
    Pharmacoepidemiol Drug Saf; 2000 May; 9(3):207-14. PubMed ID: 19025821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive Monitoring Studies for Assessing Medicines: A Systematic Review.
    Torre C; Cary M; Borges FC; Ferreira PS; Alarcão J; Leufkens HG; Costa J; Martins AP
    Front Med (Lausanne); 2019; 6():147. PubMed ID: 31380375
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.